Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug Conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The companys' flagship product Adcetris is commercially available for two indications in 50 countries, including the U.S., Canada, Japan and members of the European Union. The approval of Brentuximab vedotin makes it the first in a new class of ADCs.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the terms of the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.
|Key people||Clay B. Siegall Ph.D (Chairman, President & CEO) Todd E. Simpson (CFO Eric L. Dobmeier (Chief Operating Officer) Jean Liu (Executive Vice President Legal Affairs, General Counsel, Corporate Secretary) Jonathan Drachman M.D. (Chief Medical Officer) and Executive Vice President of R&D) Vaughn Himes (Executive Vice President) Technical Operations and Process Sciences Charles Romp (Senior Vice President) Sales Felix Baker Lead Independent Director Pinkston Peggy Senior Director Corporate Communications|
|Products||Brentuximab vedotin and other Antibody-drug conjugates|
|Headquarters||Bothell, Washington, United States|
|Founded||Incorporated 15 July 1997|
NPS is a customer loyalty metric that measures customers’ willingness to not only return for another purchase or service but also make a recommendation to their family, friends or colleagues.
It is a powerful and effective technique, which can greatly increase a company's revenue if used properly.
The main advantages of NPS are close correlation with a company's growth and easy collection, interpretation and communication of the data.
Net Promoter Score is a number from -100 from 100.
Scores higher than 0 are typically considered to be good and scores above 50 are considered to be excellent.
The industry average for Health Care / Biotechnology: Biological Products (No Diagnostic Substances) is 0.
The final Net Promoter Score of a company strongly depends on a context in which the satisfaction is measured.
Consider an example: If Seattle Genetics, Inc. sends out NPS surveys immediately after purchase, they are tracking their customers' initial excitement and the checkout experience.
On the other hand, if they survey their customers a few weeks after the purchase they are also tracking how satisfied their customers are with their products and services over time.
Therefore, comparing the NPS score of Seattle Genetics, Inc. with your own without any further context is not that useful.
What is extremely useful though, is using the NPS methodology to track the satisfaction of your customers over time. That's where Customer.guru comes in.
|Telfort||Telecommunications / Wireless Carrier||-3|
|Comcast||Consumer Brands / Car Manufacturers||-3|
|CIGNA||Insurance / Health and Life Insurance||-1|
|Chase||Financial Services / Banking||-1|
|Vodafone||Telecommunications / Wireless Carrier||-1|
|Ocado||Consumer Brands / Grocery||-4|
|Time Warner||Telecommunications / Cable/TV service||-5|
|Time Warner Cable||Telecommunications / Cable/TV service||-5|
|Sky||Telecommunications / Cable/TV service||-5|
|BBC||Media / Cable/TV service||-5|
We have estimated the Net Promoter Score of Seattle Genetics, Inc. based on the publicly available information
including the sentiment of the company-related tweets, 3rd party reviews, and Alexa ratings.